InvestorsHub Logo
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Live Updating
profile icon
dhbuzz Free
06/03/20 10:07 AM
profile icon
dhbuzz Free
06/03/20 8:22 AM
profile icon
dhbuzz Free
06/02/20 9:22 PM
profile icon
dhbuzz Free
06/02/20 9:16 PM
profile icon
dhbuzz Free
06/02/20 9:11 PM
profile icon
BrownCornSnake Free
06/02/20 2:30 PM
profile icon
dhbuzz Free
06/02/20 9:03 AM
profile icon
dhbuzz Free
06/02/20 8:51 AM
profile icon
BrownCornSnake Free
06/02/20 8:49 AM
profile icon
dhbuzz Free
06/02/20 8:47 AM
profile icon
BrownCornSnake Free
06/02/20 8:45 AM
profile icon
BrownCornSnake Free
06/02/20 8:44 AM
profile icon
dhbuzz Free
06/02/20 8:40 AM
profile icon
dhbuzz Free
06/02/20 8:38 AM
profile icon
BrownCornSnake Free
06/02/20 8:34 AM
profile icon
dhbuzz Free
06/02/20 8:25 AM
profile icon
dhbuzz Free
06/02/20 7:46 AM
profile icon
dhbuzz Free
06/02/20 6:36 AM
profile icon
dhbuzz Free
06/02/20 5:51 AM
profile icon
dhbuzz Free
06/01/20 10:11 AM
profile icon
dhbuzz Free
06/01/20 6:09 AM
profile icon
dhbuzz Free
06/01/20 5:27 AM
profile icon
cardvic Free
06/01/20 3:27 AM
profile icon
dhbuzz Free
05/31/20 8:29 PM
profile icon
dhbuzz Free
05/31/20 8:18 PM
profile icon
dhbuzz Free
05/31/20 2:57 PM
profile icon
dhbuzz Free
05/30/20 10:22 PM
profile icon
dhbuzz Free
05/30/20 11:14 AM
profile icon
Stockfun1 Free
05/30/20 11:01 AM
profile icon
dhbuzz Free
05/30/20 10:35 AM
profile icon
BrownCornSnake Free
05/30/20 10:23 AM
profile icon
dhbuzz Free
05/30/20 10:02 AM
profile icon
dhbuzz Free
05/30/20 9:19 AM
profile icon
dhbuzz Free
05/30/20 12:51 AM
profile icon
dhbuzz Free
05/30/20 12:35 AM
profile icon
dhbuzz Free
05/29/20 9:11 PM
profile icon
Stockfun1 Free
05/29/20 8:35 PM
profile icon
dhbuzz Free
05/29/20 7:47 PM
profile icon
Stockfun1 Free
05/29/20 11:46 AM
profile icon
dhbuzz Free
05/29/20 11:25 AM
profile icon
dhbuzz Free
05/29/20 11:12 AM
profile icon
dhbuzz Free
05/29/20 10:29 AM
profile icon
dhbuzz Free
05/29/20 10:25 AM
profile icon
dhbuzz Free
05/29/20 9:16 AM
profile icon
dhbuzz Free
05/29/20 8:05 AM

Zynerba Pharmaceuticals (ZYNE) RSS Feed

Followers
91
Posters
238
Posts (Today)
0
Posts (Total)
2676
Created
08/06/15
Type
Free
Moderators


Zynerba Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing synthetic cannabinoid therapeutics formulated for transdermal delivery. The Company is evaluating approximately two product candidates, ZYN002 and ZYN001, in over five indications. The Company intends to study ZYN002 in patients with refractory epilepsy, osteoarthritis and Fragile X syndrome. The Company's ZYN002 is synthetic cannabidiol (CBD) formulated as a permeation-enhanced gel for transdermal delivery. ZYN002 is being developed as a clear that is designed to provide controlled drug delivery with once- or twice-daily dosing. ZYN001 is a pro-drug of tetrahydrocannabinol (THC) that enables transdermal delivery through a patch. The Company intends to test the ZYN001 patch for application to the arm, back and thigh. The Company intends to study ZYN001 in patients with fibromyalgia and peripheral neuropathic pain.

Investor Relations

Corporate Profile

Zynerba (NASDAQ: ZYNE) is pioneering the development of patent-protected, next-generation synthetic cannabinoid therapeutics formulated for transdermal delivery. Its two lead product candidates in development include ZYN002 and ZYN001, which are being evaluated in five indications. ZYN002 is the first and only synthetic cannabidiol (CBD) formulated as a permeation-enhanced gel for transdermal delivery. In June 2016, the company initiated the STAR 1 Phase 2 clinical trial in refractory epilepsy patients and in August 2016, initiated the STOP Phase 2 clinical trial in patients with osteoarthritis of the knee. A Phase 2 clinical trial in patients with Fragile X syndrome will be initiated in the second half of 2016. 

ZYN001, a prodrug of THC that enables transdermal delivery through the skin and circulatory system via a patch, is in preclinical development. A Phase 1 clinical trial is planned in the first half of 2017.

In August 2015, Zynerba completed an initial public offering, raising net proceeds of $42.1 million. As of June 30, 2016, cash and cash equivalents totaled $32.1 million, which is projected to fund five Phase 2 clinical trials through 2017.





Zynerba Pharmaceuticals, Inc., (Nasdaq: ZYNE) announced today the pricing of its initial public offering of 3 million shares of common stock at a public offering price of $14.00 per share, before underwriting discounts. All of the shares in the offering are being sold by Zynerba. In addition, Zynerba has granted the underwriters an option to purchase up to 450,000 additional shares of common stock at the public offering price, less the underwriting discount. Zynerba's common stock has been approved for listing on the NASDAQ Global Market and is expected to begin trading under the symbol "ZYNE" on August 5, 2015.

Jefferies LLC and Piper Jaffray & Co. are acting as joint book-running managers for the offering, and Canaccord Genuity Inc. and Oppenheimer & Co. Inc. are acting as co-managers for the offering. This offering is being made only by means of a prospectus.



Extremely low float:

Fundamentals

A table providing the fundamentals of the stock
EPS (TTM) 9/30/2016 | -2.47
P/E Ratio 9/30/2016 | --
Market Cap Micro Cap | 146M
Shares Outstanding 9.95M
Float 7.2M

 

Volume:
Day Range:
Last Trade Time:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
ZYNE Latest News
  • No Recent News Available for this company!
New Post